The total return over the past 12 months is -16.56% vs. +19.98% for the S&P 500. So far it's up -11.94% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (18.44%) | +1.74% | (3.42%) | +9.91% | +10.44% | +8.02% |
| Total Return CAGR | (16.56%) | +3.89% | (1.52%) | +12.00% | +12.72% | +10.52% |
| Revenue CAGR | +8.06% | +5.01% | +2.98% | +8.53% | +1.49% | +3.80% |
| Net Income CAGR | (61.19%) | +1.68% | +7.74% | +9.07% | +0.36% | +2.78% |
| EPS CAGR | (61.41%) | +6.45% | +8.22% | +2.23% | +1.50% | +2.76% |
| Free Cash Flow CAGR | +28.71% | +16.69% | +0.18% | +17.83% | +0.48% | +3.61% |
| Operating Cash Flow CAGR | +9.60% | +9.95% | (1.40%) | +13.31% | +0.36% | +2.96% |
| Dividends CAGR | +7.28% | +7.87% | +10.39% | +9.41% | +7.26% | +7.85% |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Abbott Laboratories (ABT)
| Year | Start price | End price | ABT Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $125.29 | $108.33 | (11.94%) | +13.55% | (25.49%) |
| 2025 | $113.11 | $125.29 | +12.89% | +17.72% | (4.83%) |
| 2024 | $110.07 | $113.11 | +4.83% | +24.89% | (20.06%) |
| 2023 | $109.79 | $110.07 | +2.26% | +26.19% | (23.93%) |
| 2022 | $140.74 | $109.79 | (20.69%) | (18.17%) | (2.52%) |
| 2021 | $109.49 | $140.74 | +30.54% | +28.74% | +1.80% |
| 2020 | $86.86 | $109.49 | +28.00% | +18.37% | +9.63% |
| 2019 | $72.33 | $86.86 | +22.10% | +31.22% | (9.12%) |
| 2018 | $57.07 | $72.33 | +29.04% | (4.56%) | +33.60% |
| 2017 | $38.41 | $57.07 | +52.00% | +21.70% | +30.30% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
